Trietley Gregory S, Wilson Stephen A, Chaudhri Parul, Payette Nicole, Higbea Ashley, Nashelsky Joan
UPMC St. Margaret, Pittsburgh, PA, USA.
Texas Tech University Health Science Center, Dallas, USA.
J Fam Pract. 2017 Apr;66(4):257-263.
Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). A 2011 meta-analysis of 5 RCTs (total 2975 patients) that compared ACE inhibitor therapy with placebo in diabetic patients without hypertension and albuminuria found that ACE inhibitors reduced the risk of new-onset microalbuminuria or macroalbuminuria by 18% (relative risk [RR]=0.82; 95% confidence interval [CI], 0.73-0.92).
血管紧张素转换酶（ACE）抑制剂适用，血管紧张素受体阻滞剂（ARB）不适用。2011年一项对5项随机对照试验（共2975例患者）的荟萃分析比较了在无高血压和蛋白尿的糖尿病患者中ACE抑制剂治疗与安慰剂治疗，发现ACE抑制剂使新发微量白蛋白尿或大量白蛋白尿的风险降低了18%（相对危险度[RR]=0.82；95%置信区间[CI]，0.73 - 0.92）。
